Atezolizumab companion diagnostic - Roche

Drug Profile

Atezolizumab companion diagnostic - Roche

Alternative Names: MPDL3280A companion diagnostic; PD-L1 rabbit monoclonal immunohistochemistry antibody; Roche Tissue Diagnostics IHC assay; SP 142 immunohistochemistry antibody; Ventana PD-L1 (SP142) Assay

Latest Information Update: 25 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Developer Roche; Ventana Medical Systems
  • Class Monoclonal antibody diagnostics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Bladder cancer; Non-small cell lung cancer

Most Recent Events

  • 25 Oct 2017 Launched for Urothelial bladder cancer (Diagnosis) and Non-small cell lung cancer (Diagnosis) in USA (unspecified route) before October 2017
  • 28 Sep 2017 Registered for Bladder cancer (Diagnosis) in European Union, Iceland, Iceland, Liechtenstein and Norway (unspecified route)
  • 28 Sep 2017 Registered for Non-small cell lung cancer (Diagnosis) in European Union, Iceland, Liechtenstein and Norway (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top